Description
রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন*
Indications:
LYRINEX CR 165 MG is indicated for:
-
Neuropathic pain due to diabetic neuropathy or post-herpetic neuralgia
-
Fibromyalgia
-
Adjunctive therapy for partial-onset seizures
-
Generalized anxiety disorder (off-label in some regions)
Pharmacology:
Pregabalin CR (Controlled Release) is a GABA analogue that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the CNS. This reduces neurotransmitter release, providing relief from neuropathic pain and seizure activity. The CR formulation allows for extended drug action with once-daily dosing.
Dosage & Administration:
Usual dose: One tablet (165 mg) once daily, preferably in the evening.
Swallow whole; do not crush or chew.
Dosage adjustments should be made based on renal function and therapeutic response.
Interaction:
May potentiate CNS depressants such as opioids, sedatives, and alcohol. Monitor when used with medications that affect renal function. Minimal drug interactions reported.
Contraindications:
Hypersensitivity to Pregabalin or any other components of the formulation. Not recommended in patients with severe renal impairment without dose adjustment.
Side Effects:
Common: Dizziness, drowsiness, fatigue, blurred vision, increased appetite, and peripheral edema.
Serious: Suicidal ideation, angioedema, allergic reactions, withdrawal symptoms.
Pregnancy & Lactation:
Use only if clearly needed during pregnancy. Caution advised while breastfeeding, as pregabalin may pass into breast milk.
Precautions & Warnings:
Avoid abrupt discontinuation. Caution in patients with depression or substance abuse history. Monitor renal function regularly. May impair ability to drive or operate machinery.
Therapeutic Class:
Drugs for neuropathic pain and adjunct antiepileptics – Controlled Release Formulations
Storage Conditions:
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.
Change Language